Hepion Pharmaceuticals (NASDAQ: HEPA) director discloses holding 1,250,000 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. director LoPriore Chase filed an initial statement of beneficial ownership. The filing reports holdings of 1,250,000 shares of common stock, par value $0.0001 per share, held directly. This Form 3 reflects an existing ownership position rather than a new buy or sell transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LoPriore Chase

Role null

Type	Security	Shares	Price	Value
holding	Common Stock, par value $0.0001 per share	--	--	--

Holdings After Transaction: Common Stock, par value $0.0001 per share — 1,250,000 shares (Direct, null)

Footnotes (1)

Key Figures

Common shares owned: 1,250,000 shares Security par value: $0.0001 per share

2 metrics

Common shares owned 1,250,000 shares Total shares following holdings entry

Security par value $0.0001 per share Common Stock par value

Key Terms

Common Stock, par value, beneficial ownership

3 terms

Common Stock financial

"Common Stock, par value $0.0001 per share"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

par value financial

"Common Stock, par value $0.0001 per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

beneficial ownership financial

"filed an initial statement of beneficial ownership"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding Insider Trading Forms →

05/26/2026 - 05:00 PM

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

LoPriore Chase

(Last)

(First)

(Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK

NEW JERSEY

07701

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/16/2026

3. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $0.0001 per share	1,250,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

	/s/ Chase LoPriore	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Hepion Pharmaceuticals (HEPA) director LoPriore Chase report in this Form 3?

LoPriore Chase reports beneficial ownership of 1,250,000 shares of Hepion Pharmaceuticals common stock. This Form 3 is an initial ownership statement and does not reflect a new purchase or sale, only the existing direct holdings reported to the SEC.

How many Hepion Pharmaceuticals (HEPA) shares does LoPriore Chase directly own?

LoPriore Chase directly owns 1,250,000 shares of Hepion Pharmaceuticals common stock. This figure is shown as the total shares following the reported holdings entry and represents the director’s reported beneficial ownership position in the company at this time.

Does the Hepion Pharmaceuticals (HEPA) Form 3 show any insider buying or selling?

The Form 3 does not show any insider buying or selling activity. It records an initial holdings entry with 1,250,000 common shares and uses an unknown transaction code, indicating disclosure of an existing position rather than a new trade in the company’s stock.

Is LoPriore Chase a 10% owner of Hepion Pharmaceuticals (HEPA) according to this filing?

The filing marks LoPriore Chase as a director but not as a ten percent owner. While 1,250,000 shares are reported as held, the ten percent owner indicator is set to no, so the person is classified only in the director role here.

What type of security is reported in LoPriore Chase’s Hepion (HEPA) Form 3?

The security reported is Hepion Pharmaceuticals common stock, par value $0.0001 per share. The Form 3 records 1,250,000 shares of this common stock as directly owned, providing the SEC with details of the director’s equity stake in the company.